HomeNewsOpinionA resurgent COVID-19 strains monetary-fiscal policies, growth

A resurgent COVID-19 strains monetary-fiscal policies, growth

Policies in delicate territory as adverse combination unfolds 

April 16, 2021 / 15:42 IST
Story continues below Advertisement

A ferocious bout of coronavirus has worsened the economic environment since the April 5 monetary policy review. From then to now, daily cases have paced strong, exceeding 200,000 on April 15.

The virus’ wildfire spread displays no sign of abatement, surpassing the previous wave by a mile and more. In a further adverse twist, the slow-paced vaccination drive stumbled against supply constraints due to poor planning and lack of foresight. The obvious casualty is economic recovery and normalisation.

Story continues below Advertisement

With another round of localised but widespread restrictions, lockdowns and other curbs gathering force each day, there’s no doubt these set back the strengthening recovery. The worst part is the second successive adverse shock to growth in a year squeezes monetary and fiscal policies into a narrower space, weakening the capacity for macroeconomic responses.

Weak Position

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show